[HTML][HTML] Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Y Metaxas, G Rivalland, LA Mauti, D Klingbiel… - Journal of Thoracic …, 2018 - Elsevier
Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …
[HTML][HTML] Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Y Metaxas, G Rivalland, LA Mauti, D Klingbiel… - Journal of Thoracic …, 2018 - jto.org
Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Y Metaxas, G Rivalland, LA Mauti… - Journal of Thoracic …, 2018 - europepmc.org
Methods Registry data in Australia and Switzerland were pooled. Patient characteristics,
including age, sex, histological subtype, and previous treatments were captured. Outcomes …
including age, sex, histological subtype, and previous treatments were captured. Outcomes …
Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Y Metaxas, G Rivalland, L Mauti… - Journal of Thoracic …, 2018 - eprints.qut.edu.au
Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Y Metaxas, G Rivalland… - Journal of …, 2018 - research-repository.uwa.edu.au
Introduction: There is no approved second-line treatment for malignant pleural
mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off …
mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off …
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Y Metaxas, G Rivalland, LA Mauti, D Klingbiel… - Journal of thoracic …, 2018 - sonar.ch
METHODS Registry data in Australia and Switzerland were pooled. Patient characteristics,
including age, sex, histological subtype, and previous treatments were captured. Outcomes …
including age, sex, histological subtype, and previous treatments were captured. Outcomes …
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Y Metaxas, G Rivalland, LA Mauti, D Klingbiel… - Journal of thoracic …, 2018 - folia.unifr.ch
METHODS Registry data in Australia and Switzerland were pooled. Patient characteristics,
including age, sex, histological subtype, and previous treatments were captured. Outcomes …
including age, sex, histological subtype, and previous treatments were captured. Outcomes …
[引用][C] Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma.
Y Metaxas, G Rivalland, D Klingbiel, S Kao, S Schmid… - 2018 - ahro.austin.org.au
Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. | AHRO :
Austin Health Research Online Skip navigation Austin Health Research Online Home Research …
Austin Health Research Online Skip navigation Austin Health Research Online Home Research …
[引用][C] Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Y Metaxas, G Rivalland, LA Mauti… - Journal of Thoracic …, 2018 - espace.library.uq.edu.au
Introduction: There is no approved second-line treatment for malignant pleural
mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off …
mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off …
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Y Metaxas, G Rivalland, LA Mauti… - Journal of thoracic …, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …